Chen Liang, Li Dongqing, Zhong Jun, Qiu Bo, Wu Xianglei
Department of Orthopaedics, Renmin Hospital of Wuhan University, 9 Zhangzhidong Street, Wuhan, Hubei 430060, China.
Department of Microbiology, School of Basic Medical Science, Wuhan University, 185 Donghu Road, Wuhan, Hubei 430071, China.
Evid Based Complement Alternat Med. 2018 Jan 4;2018:6513049. doi: 10.1155/2018/6513049. eCollection 2018.
To evaluate the therapeutic effectiveness and safety of mesotherapy by comparing it with the classic systematic therapy in patients with osteoarthritis (OA).
Sixty patients were included and classified into two groups based on the existence of contraindications for nonsteroidal anti-inflammatory drugs (NSAIDs). These patients were treated with oral NSAIDs (Group A) or mesotherapy (Group B). After completing the treatment, the patients were followed up for 6 months. Their clinical features, laboratory results, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were evaluated.
A total of 50 patients completed treatment and follow-up. The patients in Group B had significantly fewer gastric acid-related complaints and requested less supplementary treatment for recurrent pain ( < 0.05). The patients in both groups exhibited decreased blood viscosity after treatment ( < 0.05). WOMAC scores, specifically those for pain and stiffness, were found to be significantly improved after either type of treatment ( < 0.05). Mesotherapy also ameliorated physical function ( < 0.05). Furthermore, Group B presented with better outcomes than Group A ( < 0.05 or < 0.01).
Our results suggest that mesotherapy is an effective and safe treatment for patients with OA. Clinicians should consider mesotherapy as an alternative therapy for patients with contraindications for NSAID use.
通过将中胚层疗法与骨关节炎（OA）患者的经典系统疗法进行比较，评估中胚层疗法的治疗效果和安全性。
纳入60例患者，根据非甾体抗炎药（NSAIDs）的禁忌证将其分为两组。这些患者分别接受口服NSAIDs治疗（A组）或中胚层疗法治疗（B组）。治疗结束后，对患者进行6个月的随访。评估他们的临床特征、实验室检查结果以及西安大略和麦克马斯特大学骨关节炎指数（WOMAC）评分。
共有50例患者完成治疗和随访。B组患者与胃酸相关的不适明显较少，因疼痛复发而需要的辅助治疗也较少（P<0.05）。两组患者治疗后血液粘度均降低（P<0.05）。两种治疗后WOMAC评分，尤其是疼痛和僵硬评分均显著改善（P<0.05）。中胚层疗法还改善了身体功能（P<0.05）。此外，B组的治疗效果优于A组（P<0.05或P<0.01）。
我们的结果表明，中胚层疗法对OA患者是一种有效且安全的治疗方法。临床医生应将中胚层疗法视为NSAID使用禁忌证患者的替代治疗方法。
